These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 37289220)

  • 1. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
    Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
    Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
    Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
    Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
    Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
    Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
    Sasagawa Y; Akai T; Tachibana O; Iizuka H
    J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
    BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.
    Ungureanu A; Le Garff-Tavernier M; Costopoulos M; Parratte T; Brinet A; Durand H; Gaultier C; Hurstel R; Alamome I; Sellal F; Ahle G
    J Neurol; 2021 Aug; 268(8):2890-2894. PubMed ID: 33609156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases.
    Yuan XG; Huang YR; Yu T; Xu Y; Liang Y; Zhang XH; Sun CR; Zhao XY
    Ann Hematol; 2020 Jan; 99(1):93-104. PubMed ID: 31758262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry.
    Krogh-Jensen M; D'Amore F; Jensen MK; Christensen BE; Thorling K; Pedersen M; Johansen P; Boesen AM; Andersen E
    Leuk Lymphoma; 1995 Oct; 19(3-4):223-33. PubMed ID: 8535213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma.
    Whitcup SM; Stark-Vancs V; Wittes RE; Solomon D; Podgor MJ; Nussenblatt RB; Chan CC
    Arch Ophthalmol; 1997 Sep; 115(9):1157-60. PubMed ID: 9298057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
    Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
    [No Abstract]   [Full Text] [Related]  

  • 13. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
    Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
    Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.
    Mizowaki T; Sasayama T; Tanaka K; Mizukawa K; Takata K; Nakamizo S; Tanaka H; Nagashima H; Nishihara M; Hirose T; Itoh T; Kohmura E
    J Neurooncol; 2015 Sep; 124(2):165-74. PubMed ID: 26080800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma.
    De Luca A; Antinori A; Cingolani A; Larocca LM; Linzalone A; Ammassari A; Scerrati M; Roselli R; Tamburrini E; Ortona L
    Br J Haematol; 1995 Aug; 90(4):844-9. PubMed ID: 7669663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
    Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
    [No Abstract]   [Full Text] [Related]  

  • 18. The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.
    Geng M; Xiao H; Liu J; Song Y; Fu P; Cheng X; Zhang J; Wang G
    Cancer Med; 2018 Aug; 7(8):3889-3898. PubMed ID: 29982995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
    Jang JE; Kim YR; Kim SJ; Cho H; Chung H; Lee JY; Park H; Kim Y; Cheong JW; Min YH; Kim JS
    Eur J Cancer; 2016 Apr; 57():127-35. PubMed ID: 26918738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome and prognostic factors in PCNSL.
    Niparuck P; Boonsakan P; Sutthippingkiat T; Pukiat S; Chantrathammachart P; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Atichartakarn V
    Diagn Pathol; 2019 Jun; 14(1):56. PubMed ID: 31189479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.